Raman Process Monitoring Probe Design Patents: Leaders & Trends 2026
- Filing has plateaued, not fallen. 2021 to 2024 filings moved from 128 to 125, a -2% shift over the complete three-year window — a mature but still-active field, not one in decline.
- No single company controls the space. The leader holds 93 records against 2,225 total in scope, and the top 5 combined account for just 14.9% of all records — filing is spread across a long tail of assignees.
- Optical and diagnostic classes overlap heavily. G01J (radiation and light measurement) touches 46.3% of records and A61B (diagnosis and surgery) touches 16.7%, showing probe design claims routinely cross into clinical instrumentation.
Filing growth compares 2021 (128 records) with 2024 (125) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 2,225 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Raman process monitoring probe design sits at the intersection of optical instrumentation and analytical chemistry: probe window materials, sterile interfaces, optical path geometry, sampling volume control and fouling resistance are the recurring claim elements across this corpus. The search scope pairs Raman-specific terminology with mechanical and interface features, then filters to G01N21/65, C12Q3/00 and G01N21/359 — the classes covering Raman spectroscopy analysis, enzymatic/DNA measurement, and fluorescence-adjacent optical testing respectively.
Coverage runs from 2015 through the 2026-07-31 cut-off, drawing on 2,225 published records. Because publication lags filing by roughly 18 months, the most recent one to two years in any trend chart will always look thinner than they eventually turn out to be — a real feature of the data, not a sign of falling activity.
Filing trend and technology composition
Two views of the same 2,225-record corpus: filing activity by year, and how records distribute across IPC subclasses. A single record can carry several IPC codes, so the composition shares add up to more than 100%.
Filing rose to a 2020 peak, then held steady
Annual filings climbed from 80 in 2017 to a peak of 170 in 2020, then eased back. The 2021-to-2024 window — the most recent stretch that can be treated as complete — moved from 128 to 125 filings, a -2% change that reads as a plateau rather than a decline. Years after 2024 are still filling in as publications catch up to filing dates.
G01N and G01J dominate; clinical and biological classes are secondary
G01N (material analysis and testing) appears on 99.6% of records, essentially defining the search scope itself. G01J (radiation and light measurement) reaches 46.3%, confirming that optical path and light-management claims are central to probe design. A61B (diagnosis and surgery, 16.7%) and G02B (optical elements, 12.3%) show meaningful secondary activity, while C12Q, C12N, G01B and B01L each sit under 4% — smaller, more specialised pockets of claim activity.
Shares are the percentage of the 2,225 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Raman Process Monitoring Probe Design with Eureka
This page is one run against one query. Ask Eureka your own question about raman process monitoring probe design and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records and a recent representative filing
Flow cell designs and integrated systems for enhanced Raman spectroscopy analysis
Discloses two flow cell geometries — a Z-design with an angled optical path and non-reflective beam dump, and a T-design with a vertical optical window sealed by O-rings — both isolating the Raman probe from direct fluid contact while minimizing dead volume and improving signal-to-noise.Filed by FiaLab Instruments; published 2025-10-30, illustrating current claim activity around sterile interface and optical path design.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5866430A | Raman optrode processes and devices for detection of chemicals and microorganisms | 412 |
| 2 | US20040073120A1 | Systems and methods for spectroscopy of biological tissue | 329 |
| 3 | US5953477A | Method and apparatus for improved fiber optic light management | 299 |
| 4 | US5842995A | Spectroscopic probe for in vivo measurement of raman signals | 299 |
| 5 | US5220403A | Apparatus and a method for high numerical aperture microscopic examination of materials | 290 |
| 6 | US5112127A | Apparatus for measuring Raman spectra over optical fibers | 246 |
| 7 | US6222970B1 | Methods and apparatus for filtering an optical fiber | 244 |
| 8 | US20040127777A1 | Indirect measurement of tissue analytes through tissue properties | 243 |
| 9 | US6040191A | Raman spectroscopic method for determining the ligand binding capacity of biologicals | 238 |
| 10 | US6662030B2 | Non-invasive sensor having controllable temperature feature | 238 |
Citation counts favour older records simply because they have had more time to accumulate citations within this searched corpus — treat them as a signal of influence on the field's foundational optical and probe designs, not as a ranking of current importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data says about where this field is headed
Three read-throughs from filing trend, concentration and citation patterns that matter for a filing or freedom-to-operate decision.
No dominant gatekeeper
The leading assignee holds 93 records and the top 5 combined reach just 14.9% of all 2,225 records in scope. Compared with fields where a handful of firms hold a third or more of filings, this is a genuinely fragmented landscape — useful for a new entrant, but it also means no single competitor's portfolio can be treated as the sole freedom-to-operate check.
A plateau, not a downturn
Filings held nearly flat between 2021 (128) and 2024 (125), the most recent window that can be read as complete. That pattern is consistent with a technology that has settled into steady, incremental claim activity around known probe architectures rather than a burst of novel filing or a retreat from the space.
Optical path claims dominate over biological ones
Nearly half of all records touch G01J (radiation and light measurement), against under 4% each for C12Q and C12N (enzyme/DNA and microorganism classes). Probe design claim activity is concentrated on light management and optical interface, with bioprocess-specific sampling claims comparatively sparse.
Foundational optrode patents still anchor the field
The most-cited record, on Raman optrode devices for detecting chemicals and microorganisms, sits well above the next tier of cited art. High citation counts here mark historical influence on probe geometry and fiber-optic light management, not necessarily current commercial relevance.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to raman process monitoring probe design, with the prior art for and against each one.
Who is filing, and what is still open
The ranking covers 100 companies across 2,225 records. Filing is led by a small group of instrumentation specialists but stays a long-tail field — most named assignees hold only a handful of records each.
A specialist instrumentation leader, not a conglomerate
The top-ranked assignee's 93 records are built almost entirely from Raman-specific optical and probe hardware rather than a diversified corporate portfolio, consistent with the field's roots in dedicated spectroscopy instrument makers.
A steep drop after the top few
Filing counts fall from 41 at fifth place to 27 at tenth, and the top 10 combined reach 21.7% of all 2,225 records. Beyond that point, the ranking is dominated by companies with far smaller, more specialised filing footprints.
Momentum has cooled even among top filers
Several of the most active historical assignees show only one or zero filings in the latest tracked year, including one leader recording a -100% year-over-year change. That is consistent with the corpus-wide plateau rather than any single company's retreat.
| Assignee | Recent year | YoY |
|---|---|---|
| Massachusetts Institute of Technology (MIT) | 1 | — |
| Nova Measuring Instruments Ltd. | 1 | 0% |
| Photothermal Spectroscopy Corp. | 1 | — |
| ChemImage Corp. | 0 | — |
| Renishaw plc | 0 | -100% |
| Atonarp Inc. | 0 | — |
| Apollon Inc. | 0 | -100% |
| UK Science and Technology Facilities Council | 0 | — |
Where to take this analysis
The dataset points to specific follow-up questions depending on whether you are filing, licensing or clearing a design.
Map the optical path claim space
With G01J touching 46.3% of records, a freedom-to-operate check on any new probe window or beam-path design should start with the optical measurement class rather than the broader G01N bucket.
Explore optical path claims in EurekaWatch the bioprocess-adjacent classes
C12Q and C12N each sit under 4% of records, suggesting comparatively open claim space for probe designs aimed at enzymatic or microbial sampling rather than general optical measurement.
Run a white space search in EurekaTrack leader momentum, not just leader size
Several top-ranked assignees show flat or falling recent-year filing counts, so current competitive pressure may not match historical portfolio size.
Set up assignee alerts in EurekaCommon questions about this landscape
The leading assignee in this corpus holds 93 of the 2,225 records in scope, well ahead of the fifth-ranked company at 41. However, the top 5 assignees combined account for only 14.9% of all records, so no single company controls enough of the filing space to be treated as the sole gatekeeper. A freedom-to-operate review should look across the full 100-company ranking rather than assuming the leader's portfolio covers the field.
Filing peaked at 170 records in 2020 and has since settled into a plateau: the 2021-to-2024 window, the most recent stretch complete enough to read reliably, moved from 128 to 125 filings, a -2% change. That is a mature, steady field rather than one in decline. Figures for 2025 and 2026 will look lower simply because publication lags filing by roughly 18 months, so they should not be read as a downturn yet.
G01N (material analysis and testing) appears on 99.6% of records because it effectively defines the search scope, but the more informative class is G01J (radiation and light measurement) at 46.3%, which reflects the centrality of optical path and light-management claims. A61B (diagnosis and surgery) and G02B (optical elements) follow at 16.7% and 12.3%. Because records can carry multiple IPC codes, these shares are not mutually exclusive and add up to more than 100%.
This 2025 filing from FiaLab Instruments discloses two flow cell geometries for Raman spectroscopy — a Z-design with an angled optical path and non-reflective beam dump, and a T-design with a vertical optical window sealed by O-rings. Both isolate the Raman probe from direct fluid contact while minimizing dead volume. It is a useful recent marker of where sterile-interface and optical-path claim activity currently sits, though it is too new to have accumulated meaningful citations.
The technology composition data shows C12Q (enzyme and DNA measurement) and C12N (microorganism and genetic engineering) each cover under 4% of the 2,225 records, well below the 46.3% share held by general optical measurement classes. That gap suggests probe designs aimed specifically at enzymatic or microbial sampling interfaces, rather than generic optical path or window claims, are comparatively under-claimed relative to the field's overall filing density.
Research Raman Process Monitoring Probe Design in depth with Eureka
Go past this page: query the whole raman process monitoring probe design corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.